Biofrontera Inc. (BFRI)
After hours:
| Previous Close | 0.8890 |
| Open | 0.8979 |
| Bid | 0.8700 x 1100 |
| Ask | 0.9000 x 1000 |
| Day's Range | 0.8500 - 0.9300 |
| 52 Week Range | 0.7500 - 6.1200 |
| Volume | |
| Avg. Volume | 108,329 |
| Market Cap | 23.498M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.5900 |
| Earnings Date | Nov 14, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.50 |
- Simply Wall St.
Breakeven On The Horizon For Biofrontera Inc. (NASDAQ:BFRI)
With the business potentially at an important milestone, we thought we'd take a closer look at Biofrontera Inc.'s...
- ACCESSWIRE
Biofrontera Inc. Announces First Patient Dosed in Pivotal Phase 3 Clinical Study Evaluating Ameluz(R)-PDT for the Treatment of Actinic Keratosis on the Extremities, Neck and Trunk
Biofrontera Inc. (Nasdaq:BFRI),a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that the first patient has been dosed in a Phase 3 randomized, double-blind, vehicle-controlled, multicenter clinical study to evaluate the safety and efficacy of Ameluz® and BF-RhodoLED® XL in the field-directed treatment of actinic keratosis (AK) on the extremities, neck and trunk.
- ACCESSWIRE
Biofrontera Inc. Announces Preliminary Revenues for the Fourth Quarter and Full Year 2022
Biofrontera Inc. (Nasdaq:BFRI),a biopharmaceutical company specializing in the commercialization of dermatological products, today announced preliminary, unaudited revenues for the three and 12 months ended December 31, 2022.
